ELCC 2016 | Clinical trial designs and ongoing trials in immunotherapy for lung cancer

David Carbone

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, explains that there has been significant progress in the development of immunotherapy for lung cancer and clinical trial design in immunotherapy should be tailored to the patterns of response and outcomes observed for this approach.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter